436 related articles for article (PubMed ID: 22981608)
1. Remission of psoriasis after allogeneic, but not autologous, hematopoietic stem-cell transplantation.
Kaffenberger BH; Wong HK; Jarjour W; Andritsos LA
J Am Acad Dermatol; 2013 Mar; 68(3):489-92. PubMed ID: 22981608
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of autologous and allogeneic hematopoietic stem cell transplantation for 140 patients with de novo acute leukemia in first complete remission].
Wang HH; Feng SZ; Wang M; Wei JL; Jiang EL; Zhang L; Huang Y; Zhou SY; Liu QG; Qiu LG; Han MZ; Yan WW
Zhonghua Xue Ye Xue Za Zhi; 2004 Jul; 25(7):389-92. PubMed ID: 15355688
[TBL] [Abstract][Full Text] [Related]
3. Second allogeneic hematopoietic stem cell transplantation as treatment for leukemia relapsing following a first transplant.
Blau IW; Basara N; Bischoff M; Günzelmann S; Römer E; Kirsten D; Schmetzer B; Kiehl MG; Fauser AA
Bone Marrow Transplant; 2000 Jan; 25(1):41-5. PubMed ID: 10654013
[TBL] [Abstract][Full Text] [Related]
4. Haematopoetic stem cell transplantation for refractory autoimmune cytopenia.
Passweg JR; Rabusin M; Musso M; Beguin Y; Cesaro S; Ehninger G; Espigado I; Iriondo A; Jost L; Koza V; Lenhoff S; Lisukov I; Locatelli F; Marmont A; Philippe P; Pilatrino C; Quartier P; Stary J; Veys P; Vormoor J; Wahlin A; Zintl F; Bocelli-Tyndall C; Tyndall A; Gratwohl A;
Br J Haematol; 2004 Jun; 125(6):749-55. PubMed ID: 15180864
[TBL] [Abstract][Full Text] [Related]
5. [Hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia].
Liu QF; Sun J; Zhang Y; Liu XL; Xu D; Xu B; Feng R; Meng FY; Zhou SY
Ai Zheng; 2004 Apr; 23(4):426-9. PubMed ID: 15087032
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of high-dose therapy and hematopoietic stem cell transplantation for mantle cell lymphoma.
Laudi N; Arora M; Burns L; McGlave P; Miller J; Bohac G; Rogers T; Barker J; Coad J; Weisdorf D
Am J Hematol; 2006 Jul; 81(7):519-24. PubMed ID: 16755570
[TBL] [Abstract][Full Text] [Related]
7. Effect of allogeneic hematopoietic stem cell transplantation from matched siblings or unrelated donors during the first complete remission in patients with cytogenetically normal acute myeloid leukemia.
Hsieh YY; Hong YC; Hsiao LT; Yu YB; Liu JH; Gau JP; Lin HN; Hsu YN; Chiou TJ; Chen PM; Tzeng CH; Liu CY
Eur J Haematol; 2011 Mar; 86(3):237-45. PubMed ID: 21155895
[TBL] [Abstract][Full Text] [Related]
8. High-dose melphalan with or without stem cell support before myeloablative allo-SCT for remission induction in patients with advanced relapsed or refractory AML.
O'Meara A; Pabst T; Heim D; Gerull S; Bucher C; Halter J; Arber C; Rovò A; Tichelli A; Gratwohl A; Stern M
Bone Marrow Transplant; 2011 May; 46(5):636-40. PubMed ID: 20697364
[TBL] [Abstract][Full Text] [Related]
9. Secondary failure of platelet recovery after hematopoietic stem cell transplantation.
Bruno B; Gooley T; Sullivan KM; Davis C; Bensinger WI; Storb R; Nash RA
Biol Blood Marrow Transplant; 2001; 7(3):154-62. PubMed ID: 11302549
[TBL] [Abstract][Full Text] [Related]
10. The harvest and use of autologous back-up grafts for graft failure or severe GVHD after allogeneic hematopoietic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation.
Stelljes M; van Biezen A; Slavin S; Olavarria E; Clark RE; Nagler A; Koza V; Kienast J; Niederwieser D; de Witte T; Ruutu T;
Bone Marrow Transplant; 2008 Dec; 42(11):739-42. PubMed ID: 18724394
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes of hematopoietic stem cell transplantation for severe treatment-resistant autoimmune cytopenia in children.
Rabusin M; Snowden JA; Veys P; Quartier P; Dalle JH; Dhooge C; Di Bartolomeo P; Gonzalez-Vicent M; Gibson B; Iriondo A; Juergens H; Lisukov I; Messina C; Mialou V; Steward CG; Urban C; Renard M; Giurici N; Peters C; Badoglio M; Ronfani L; Dini G; Farge D; Saccardi R;
Biol Blood Marrow Transplant; 2013 Apr; 19(4):666-9. PubMed ID: 23253561
[TBL] [Abstract][Full Text] [Related]
12. High rate of long-term survival for high-risk lymphoma patients treated with hematopoietic stem cell transplantation as consolidation or salvage therapy.
Espigado I; Ríos E; Marín-Niebla A; Carmona M; Parody R; Pérez-Hurtado JM; Márquez FJ; Urbano-Ispizua A
Transplant Proc; 2008 Nov; 40(9):3104-5. PubMed ID: 19010208
[TBL] [Abstract][Full Text] [Related]
13. Shortening of telomeres in recipients of both autologous and allogeneic hematopoietic stem cell transplantation.
Akiyama M; Asai O; Kuraishi Y; Urashima M; Hoshi Y; Sakamaki H; Yabe H; Furukawa T; Yamada O; Mizoguchi H; Yamada H
Bone Marrow Transplant; 2000 Feb; 25(4):441-7. PubMed ID: 10723589
[TBL] [Abstract][Full Text] [Related]
14. Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia.
Platzbecker U; Thiede C; Füssel M; Geissler G; Illmer T; Mohr B; Hänel M; Mahlberg R; Krümpelmann U; Weissinger F; Schaich M; Theuser C; Ehninger G; Bornhäuser M
Leukemia; 2006 Apr; 20(4):707-14. PubMed ID: 16482208
[TBL] [Abstract][Full Text] [Related]
15. Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome.
Zeiser R; Deschler B; Bertz H; Finke J; Engelhardt M
Bone Marrow Transplant; 2004 Dec; 34(12):1057-65. PubMed ID: 15516937
[TBL] [Abstract][Full Text] [Related]
16. Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation.
Hong JY; Choi MK; Kim DH; Kim SJ; Kim K; Kim WS; Chung CW; Kim HO; Min YH; Jang JH
Transplant Proc; 2010 Nov; 42(9):3723-8. PubMed ID: 21094846
[TBL] [Abstract][Full Text] [Related]
17. Identical outcome after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8;21): a retrospective study from the European Cooperative Group for Blood and Marrow Transplantation.
Gorin NC; Labopin M; Frassoni F; Milpied N; Attal M; Blaise D; Meloni G; Iori AP; Michallet M; Willemze R; Deconninck E; Harousseau JL; Polge E; Rocha V
J Clin Oncol; 2008 Jul; 26(19):3183-8. PubMed ID: 18506024
[TBL] [Abstract][Full Text] [Related]
18. The EBMT activity survey 2006 on hematopoietic stem cell transplantation: focus on the use of cord blood products.
Gratwohl A; Baldomero H; Frauendorfer K; Rocha V; Apperley J; Niederwieser D; ;
Bone Marrow Transplant; 2008 Apr; 41(8):687-705. PubMed ID: 18084334
[TBL] [Abstract][Full Text] [Related]
19. Change in stem cell source for hematopoietic stem cell transplantation (HSCT) in Europe: a report of the EBMT activity survey 2003.
Gratwohl A; Baldomero H; Schmid O; Horisberger B; Bargetzi M; Urbano-Ispizua A
Bone Marrow Transplant; 2005 Oct; 36(7):575-90. PubMed ID: 16086045
[TBL] [Abstract][Full Text] [Related]
20. Treatment of peripheral T-cell lymphomas (PTCL) with high-dose chemotherapy and autologous or allogeneic hematopoietic transplantation.
Kahl C; Leithäuser M; Wolff D; Steiner B; Hartung G; Casper J; Freund M
Ann Hematol; 2002 Nov; 81(11):646-50. PubMed ID: 12454703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
